Ignite Creation Date:
2024-10-25 @ 8:06 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06559371
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-15
Brief Title:
68Ga FAPI PETCT Evaluation of Axillary Lymph Node Status After Neoadjuvant Therapy in Patients With Clinical Axillary Lymph Node Positive Breast Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
68Ga FAPI PETCT Evaluation of Axillary Lymph Node Status After Neoadjuvant Therapy in Patients With Clinical Axillary Lymph Node Positive Breast Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this observational study is to learn whether 68Ga-FAPI PETCT may be used as a new effective methods for evaluating axillary lymph node efficacy after neoadjuvant treatment for breast cancer The main question it aims to answer is
Could 68Ga-FAPI PETCT effectively evaluate axillary lymph node after neoadjuvant treatment for breast cancer Participants will have a 68Ga-FAPI PETCT test between last neoadjuvant therapy and surgery
Could 68Ga-FAPI PETCT effectively evaluate axillary lymph node after neoadjuvant treatment for breast cancer Participants will have a 68Ga-FAPI PETCT test between last neoadjuvant therapy and surgery
Detailed Description:
Previous studies have shown that compared with conventional 18F-FDG PETCT 68Ga-FAPI PETCT has the characteristics of not being affected by blood glucose good tumor specificity and high tumor-to-background ratio and studies have shown that 68Ga- FAPI PETCT can detect parts of breast cancer primary lesions and lymph node metastases with low 18F-FDG uptake thereby increasing the lesion detection rate and improving the sensitivity of imaging examinations Therefore 68Ga-FAPI PETCT may be used as a new effective methods for evaluating axillary lymph node efficacy after neoadjuvant treatment for breast cancer Therefore we plan to conduct this study to explore the ability of 68Ga-FAPI PETCT to detect residual disease in axillary lymph nodes in patients with clinically positive axillary node cN breast cancer after neoadjuvant treatment By this way we may explore an accurate and non-invasive assessment of axillary lymph node status after neoadjuvant therapy in breast cancer patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None